MarketCapExport financials
China Pharma Holdings (CPHI)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
China Pharma Holdings Income Statement 2025-2009 | CPHI
Brief overview of profit and loss at China Pharma Holdings
The conclusions below are based on five years of reported results. According to figures from China Pharma Holdings, revenue changed from 10.9 million dollars to 4.1 million dollars over five years. The five-year change reached −61.9%, while CAGR stood at −17.5%. Sales followed a declining trajectory over the five years.
Gross profit changed from 2 million dollars to −132 thousand dollars (−106.8%). The relationship between sales and direct costs deteriorated. Comparing the endpoints gives gross margins of 18% and −3.2%. Weakening gross profitability reduces the quality of the top-line trend.
The five-year EBITDA result moved by −902.1%: from $216 thousand to −$1.7 million. EBITDA lagged revenue, showing weaker operating momentum. At the operating-margin level, the figure shifted from 2% to −41.9%. The margin contraction indicates weaker operating efficiency.
Net income moved from −2.9 million dollars at the start to −3.2 million dollars at the end. Larger losses indicate rising pressure on the business.
Financial takeaway
The current trajectory does not yet confirm a sustainable recovery. The most visible risks are weak sales momentum, pressure from direct costs and declining net profitability. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement China Pharma Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
2.75 M | 454 K | 1.25 M | 368 K | 2.21 M | 30.9 M | 18.3 M | 12.6 M | 14.8 M | 10.9 M | 6.1 M | 13.1 M | 18.7 M | 10.9 M | 33 M | 59.2 B | 30 B |
Shares |
4.29 M | 1.75 M | 3.38 M | 1.05 M | 4.61 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.5 M | 43.4 M | 42.3 M |
Historical Prices |
0.64 | 0.26 | 0.37 | 0.35 | 0.48 | 0.45 | 0.24 | 0.26 | 0.18 | 0.26 | 0.16 | 0.3 | 0.35 | 0.2 | 0.67 | 1.36 K | 710 |
Net Income |
-3.19 M | -4.74 M | -3.08 M | -3.97 M | -3.4 M | -2.87 M | -20.7 M | -10.8 M | -19.3 M | -9.18 M | -15.4 M | -26 M | -20 M | 4.62 M | 19.3 M | 23.4 M | - |
Revenue |
4.14 M | 4.53 M | 7.01 M | 8.1 M | 9.64 M | 10.9 M | 10.9 M | 12.3 M | 13.2 M | 15.6 M | 20.4 M | 24.9 M | 32.8 M | 54.5 M | 81.2 M | 74.4 M | - |
Cost of Revenue |
4.28 M | 6.51 M | 7.29 M | 8.6 M | 9.29 M | 8.91 M | 9.44 M | 10.4 M | 10.7 M | 12.4 M | 15.8 M | 17.2 M | 23.4 M | 38.7 M | 52.2 M | 44.1 M | - |
Gross Profit |
-132 K | -1.99 M | -281 K | -494 K | 349 K | 1.95 M | 1.48 M | 1.97 M | 2.47 M | 3.22 M | 1.46 M | 5.46 M | -481 K | 14.1 M | 29 M | 30.3 M | - |
Operating Income |
-3.24 M | -4.59 M | -2.75 M | -3.55 M | -2.86 M | -2.58 M | -20.4 M | -10.4 M | -18.7 M | -8.16 M | -14.3 M | -38.8 M | -18.6 M | 5.91 M | 22 M | 24.7 M | - |
Interest Expense |
27.3 K | 27.4 K | 30.6 K | 435 K | 542 K | 294 K | 322 K | 451 K | 539 K | 850 K | -1.17 M | 786 K | -349 K | -308 K | -255 K | -168 K | - |
EBITDA |
-1.74 M | -1.97 M | 1.83 K | -848 K | 227 K | 216 K | -461 K | -105 K | 189 K | -28.8 K | -449 K | -549 K | -6.24 M | 8.83 M | 23.2 M | 26.2 M | - |
Operating Expenses |
3.11 M | 2.6 M | 2.47 M | 3.06 M | 3.21 M | 4.42 M | 4.87 M | 5.34 M | 5.57 M | 6.33 M | 5.51 M | 7.8 M | 7.37 M | 6.71 M | 6.96 M | 6.09 M | - |
General and Administrative Expenses |
2.45 M | 1.78 M | 1.47 M | 1.89 M | 1.65 M | 1.82 M | 2.29 M | 1.95 M | 2.02 M | 2.27 M | 1.9 M | 1.72 M | 2.4 M | 3.31 M | 3.72 M | 3.04 M | - |
All numbers in USD currency
Quarterly Income Statement China Pharma Holdings
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
25.6 M | 3.87 M | 3.26 M | 3.26 M | 3.26 M | 1.73 M | 1.61 M | 1.33 M | 10.6 M | 2.64 M | 1.69 M | 8.08 M | 7.49 M | 5 M | 4.85 M | 4.74 M | 47.3 M | 46 M | 45.6 M | 45.6 M | 45.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.5 M | 43.5 M | 43.5 M | 43.5 M |
Net Income |
-1.14 M | -651 K | -528 K | -786 K | - | -1.12 M | -1.44 M | -956 K | - | -778 K | -593 K | -476 K | - | -791 K | -888 K | -1.03 M | - | -827 K | -825 K | -767 K | - | -1.01 M | 13.1 K | -661 K | - | -701 K | -838 K | -418 K | - | -1.86 M | -1.01 M | -293 K | - | -2.2 M | -2.29 M | -967 K | - | -1.75 M | -2.45 M | -1.55 M | - | 2.93 M | 1.13 M | -4.07 M | - | -6.33 M | -8.64 M | -2.39 M | - | -9.58 M | -4.46 M | 287 K | - | 5.86 M | 4.57 M | 2.81 M | - | 3.29 M | 5.07 M | 5.1 M |
Revenue |
984 K | 756 K | 1.03 M | 1.14 M | - | 1.1 M | 925 K | 1.37 M | - | 1.8 M | 1.1 M | 1.96 M | - | 1.97 M | 1.61 M | 1.6 M | - | 1.98 M | 2.42 M | 2.36 M | - | 2.4 M | 3.77 M | 1.76 M | - | 2.38 M | 2.57 M | 2.93 M | - | 2.3 M | 3.17 M | 3.62 M | - | 3.16 M | 2.92 M | 3.29 M | - | 3.13 M | 3.54 M | 3.64 M | - | 4.48 M | 5.67 M | 5.69 M | - | 5.57 M | 6.13 M | 7.11 M | - | 8.12 M | 8.03 M | 8.25 M | - | 12.2 M | 14.6 M | 16.1 M | - | 21 M | 19.6 M | 18.1 M |
Cost of Revenue |
698 K | 816 K | 1.11 M | 1.27 M | - | 1.62 M | 1.94 M | 1.66 M | - | 2.04 M | 1.24 M | 1.78 M | - | 2.1 M | 1.84 M | 1.77 M | - | 2.28 M | 2.34 M | 2.09 M | - | 2.35 M | 2.62 M | 1.57 M | - | 2 M | 2.41 M | 2.27 M | - | 1.79 M | 2.59 M | 2.56 M | - | 2.74 M | 2.27 M | 2.57 M | - | 2.78 M | 3.06 M | 3 M | - | 3.72 M | 4.51 M | 4.43 M | - | 4.06 M | 3.71 M | 4.45 M | - | 5.86 M | 5.85 M | 6.13 M | - | 8.93 M | 10.5 M | 10.8 M | - | 13.5 M | 12.3 M | 11.2 M |
Gross Profit |
285 K | -59.7 K | -87 K | -136 K | - | -520 K | -1.02 M | -290 K | - | -233 K | -147 K | 178 K | - | -138 K | -229 K | -169 K | - | -296 K | 71 K | 273 K | - | 47.2 K | 1.15 M | 194 K | - | 373 K | 164 K | 657 K | - | 513 K | 579 K | 1.05 M | - | 422 K | 648 K | 718 K | - | 350 K | 482 K | 641 K | - | 322 K | -55.8 K | 1.06 M | - | 1.51 M | 2.42 M | 2.66 M | - | 2.24 M | 2.15 M | -1.57 M | - | 3.24 M | 4.14 M | 5.3 M | - | 7.51 M | 7.28 M | 6.87 M |
Operating Income |
-1.12 M | -628 K | -652 K | -759 K | - | -1.09 M | -1.39 M | -916 K | - | -714 K | -456 K | -397 K | - | -689 K | -780 K | -912 K | - | -762 K | -753 K | -696 K | - | -952 K | 75 K | -599 K | - | -645 K | -753 K | -334 K | - | -1.93 M | -864 K | -141 K | - | -2.06 M | -2.13 M | -803 K | - | -1.55 M | -2.22 M | -1.32 M | - | 3.19 M | 1.44 M | -3.76 M | - | -5.99 M | -8.53 M | -2.34 M | - | -2.69 M | -4.76 M | -3 M | - | 1.62 M | 2.21 M | 3.41 M | - | 5.96 M | 5.76 M | 5.34 M |
Interest Expense |
9.08 K | 6.8 K | 6.78 K | 6.79 K | - | 6.84 K | 6.85 K | 6.86 K | - | 6.94 K | 138 K | 79.4 K | - | 104 K | 110 K | 124 K | - | 64.9 K | 72.4 K | 71.3 K | - | 61.1 K | 63.1 K | 62 K | - | 67.6 K | 97.3 K | 86.8 K | - | 102 K | 131 K | 129 K | - | 131 K | 142 K | 139 K | - | 214 K | 244 K | -242 K | - | 279 K | 322 K | 314 K | - | -325 K | -113 K | -56.4 K | - | -89.2 K | -92 K | 82.4 K | - | -79.5 K | -78.5 K | -77.5 K | - | -62.4 K | -61.2 K | -61.2 K |
EBITDA |
-137 K | -470 K | -489 K | -429 K | - | -592 K | -755 K | -182 K | - | -83 K | 185 K | 244 K | - | -33.3 K | -770 K | -238 K | - | 1.61 M | 648 K | 3.72 K | - | 1.03 M | 1.38 M | 56.6 K | - | 1.62 M | 823 K | 461 K | - | 568 K | 850 K | 721 K | - | 393 K | -503 K | 12.8 K | - | 1.04 M | -493 K | -464 K | - | 5.96 M | 3.32 M | -2.81 M | - | -4.98 M | -7.93 M | -2.04 M | - | -1.65 M | -4.06 M | -2.96 M | - | 2.71 M | 2.94 M | 3.78 M | - | 7.05 M | 6.65 M | 5.78 M |
Operating Expenses |
1.4 M | 568 K | 565 K | 623 K | - | 566 K | 376 K | 626 K | - | 480 K | 310 K | 575 K | - | 551 K | 550 K | 742 K | - | 466 K | 824 K | 969 K | - | 1 M | 1.07 M | 794 K | - | 1.02 M | 917 K | 991 K | - | 2.44 M | 1.44 M | 1.19 M | - | 2.48 M | 2.78 M | 1.52 M | - | 1.9 M | 3.05 M | 1.96 M | - | -1.22 M | -1.49 M | 4.82 M | - | 7.57 M | 10.9 M | 5 M | - | 4.92 M | 6.91 M | 1.43 M | - | 1.63 M | 1.93 M | 1.89 M | - | 1.55 M | 1.67 M | 1.53 M |
General and Administrative Expenses |
1.23 M | 425 K | 441 K | 507 K | - | 345 K | 91.9 K | 488 K | - | 246 K | 112 K | 418 K | - | 277 K | 273 K | 514 K | - | 302 K | 330 K | 409 K | - | 291 K | 322 K | 389 K | - | 334 K | 335 K | 429 K | - | 327 K | 353 K | 492 K | - | 349 K | 612 K | 417 K | - | 294 K | 781 K | 319 K | - | 384 K | 459 K | 472 K | - | 423 K | 383 K | 424 K | - | 373 K | 591 K | 573 K | - | 598 K | 813 K | 676 K | - | 621 K | 987 K | 917 K |
All numbers in USD currency
The income statement is one of the three key financial reports of a company China Pharma Holdings (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Canada
Irlanda
Schweden
France
